New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
08:13 EDTAMRNAmarin to present data showing Vascepa significantly reduced ApoC-III levels
Amarin announced the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa capsules significantly reduced apolipoprotein C-III, or ApoC-III, levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride metabolism. Steven B. Ketchum, Ph.D., president of research and development, senior vice president, Amarin stated, "The significantly reduced Apo C-III levels with Vascepa in the MARINE and ANCHOR trials add to previously reported TG- and ApoB-lowering effects in patients from these studies. We are pleased to continue to analyze and share data from these trials that support the clinical value of Vascepa as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia."
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
16:50 EDTAMRNAmarin files $300M mixed securities shelf
16:12 EDTAMRNAmarin reports Q2 adjusted EPS (14c), consensus (15c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use